Skip to content

Arvinas ARVN Shares (Basic)

Shares (Basic) at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
110.1M+31.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
97.5M+21.7%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
99.9M+21.6%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
86.6M+185%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
23.4M+17.4%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
45.1M+32.9%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's shares (basic)?
Arvinas (ARVN) reported shares (basic) of 64M in Q1 2026.
How has Arvinas's shares (basic) changed year-over-year?
Arvinas's shares (basic) decreased by 11.7% year-over-year, from 72.5M to 64M.
What is the long-term trend for Arvinas's shares (basic)?
Over 4 years (2021 to 2025), Arvinas's shares (basic) has grown at a 10.1% compound annual growth rate (CAGR), from 197.3M to 289.6M.
What does shares (basic) mean?
The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.